- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03072485
Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers
March 28, 2019 updated by: Anne Chang
This is a phase 1 study in healthy adult volunteers to examine the effects of 3 FDA approved medications on skin aging when applied in topical form.
This is an open label, placebo controlled study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The primary endpoint of the study is the profile of differences in transcript levels of age-associated genes such as those in the lamin-A, insulin like growth factor (IGF) and NFKB pathways as well as noncoding RNAs in topical agent-exposed arm skin versus placebo exposed arm skin in healthy volunteers.
The secondary endpoints include (1) differences in skin wrinkling using a 4 point Likert scale for wrinkle severity between placebo and topical agent exposed arm skin after 4 weeks of usage; (2) the type and severity of adverse events, both systemic and skin localized after exposure to both topical agent and placebo vehicle cream.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Redwood City, California, United States, 94603
- Stanford Dermatology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
55 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Age greater than or equal to 55 years
- Female
- All 4 grandparents of European descent
- Fitzpatrick Skin type 1-3 (fair skin type)
- Presence of moderate to severe fine wrinkling on arm skin
- Presence of moderate to severe dyspigmentation on arm skin
- Normal or overweight body mass index
Exclusion Criteria:
- History of laser treatment or chemical peels to to arm
- History of topical anti-aging products (includes retinol, tretinoin, tazarotene, azelaic acid, hydroquinone) to skin within 6 weeks of starting study
- History of surgical procedures to arm skin area including removal of benign or malignant skin cancers in the area of topical study agent application
- Current skin conditions in the area of arms including seborrheic keratosis, rosacea, eczema that may obscure study assessment
- History of abnormal scarring
- Uncontrolled medical problems including concurrent infection or malignancy at time of enrollment
- Unable to provide and sign written informed consent
- Unable to comply with study-related procedures including keeping study diary, application of topical study agents, avoidance of direct sun exposure >5 minutes per day or ultraviolet tanning bed usage
- Not willing to provide two small skin biopsies at end of study
- Known allergy to sirolimus, diclofenac or metformin.
- Known immunosuppression including organ transplant, HIV, autoimmune disease, and chronic leukemia or lymphoma
- Fasting blood sugar above the upper limit of normal for Stanford laboratory
- Diarrhea
- Use of greater than one alcoholic beverage per day
- Stress such as surgery or trauma within 2 weeks of enrollment
- Liver disease such as hepatitis B or C
- Planning to embark on dieting, caloric restriction or new exercise regimen during the study to lose weight.
- Unable to refrain from using any topical agent on arms besides the study agents provided for duration of study.
- Hematocrit, hemoglobin, platelets, white blood cell count, serum Na, K, Cr, aspartate aminotransferase (AST), alanine aminotransferase (ALT) greater or lesser than 1.5 times limits of normal.
- History of heart failure, coronary artery disease, including angina, coronary artery bypass graft, pacemaker or stent placement
- History of bleeding or ulcers of the gastrointestinal tract
- History of diabetes mellitus
- Current use of blood thinners (includes heparin, warfarin and aspirin)
- Current use of strong cytochrome P 450 (CYP) 3A4 inhibitor and/or P-gp (examples include ketoconazole, voriconazole, itraconazole, erythromycin, clarithromycin) or strong inducers of CYP3A4 and/or P-gp (examples include rifampin or rifabutin)
- Abnormal lipid panel as defined by upper limit of normal at Stanford laboratory
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Sirolimus, metformin, diclofenac
First five enrolled participants
|
Topical sirolimus applied to the skin
Topical metformin applied to the skin
Topical diclofenac applied to the skin
|
OTHER: Metformin, diclofenac
Sixth to tenth enrolled participants
|
Topical metformin applied to the skin
Topical diclofenac applied to the skin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Profile of gene transcript changes
Time Frame: 4 weeks
|
Profile of gene transcript changes
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wrinkle score
Time Frame: 4 weeks
|
on Likert scale
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Anne Chang, MD, Stanford University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
March 1, 2017
Primary Completion (ACTUAL)
February 22, 2019
Study Completion (ACTUAL)
February 22, 2019
Study Registration Dates
First Submitted
February 27, 2017
First Submitted That Met QC Criteria
March 1, 2017
First Posted (ACTUAL)
March 7, 2017
Study Record Updates
Last Update Posted (ACTUAL)
April 1, 2019
Last Update Submitted That Met QC Criteria
March 28, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Metformin
- Diclofenac
- Sirolimus
Other Study ID Numbers
- IRB-37203
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aging
-
Tuba MadenCompletedAging | Aging Problems | Aging Disorder
-
Radboud University Medical CenterNot yet recruitingAging | Aging Well | Immuno Aging
-
University of Santiago de CompostelaEuropean Regional Development Fund; Center for Industrial Technological Development...Completed
-
TruDiagnosticBlushield USANot yet recruitingAging | Aging Well
-
San Diego State UniversityCompleted
-
Lithuanian Sports UniversityCompletedAging | Healthy AgingLithuania
-
University of West AtticaNot yet recruiting
-
University of Santiago de CompostelaAgencia Estatal de Investigación, SpainRecruiting
-
Beijing HospitalBGI-ShenzhenCompletedAging | Healthy Aging
-
Amazentis SAproDERM GmbHCompleted
Clinical Trials on Sirolimus
-
Aadi Bioscience, Inc.Approved for marketingTSC1 | TSC2 | PEComa, Malignant | mTOR Pathway Abberation
-
Johns Hopkins UniversityMacuSight, Inc.CompletedPanuveitis | Uveitis | Posterior Uveitis | Intermediate UveitisUnited States
-
Aadi Bioscience, Inc.CompletedHigh Grade Recurrent Glioma and Newly Diagnosed GlioblastomaUnited States
-
Stefan Schieke MDWithdrawnCutaneous T-cell Lymphoma (CTCL)United States
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedLymphangioleiomyomatosisUnited States
-
The University of Texas Health Science Center,...Society for Pediatric DermatologyCompletedTuberous Sclerosis | Neurofibromatoses | Neurofibroma | AngiofibromaUnited States
-
Xijing HospitalAir Force Military Medical University, China; Shanghai MicroPort Medical (Group)... and other collaboratorsUnknown
-
Shanghai Jiao Tong University School of MedicineUnknownCoronary Artery DiseaseChina
-
Paul S Teirstein, MDCordis CorporationCompletedCoronary Artery Disease | Coronary Thrombosis | Coronary RestenosisUnited States
-
Meril Life Sciences Pvt. Ltd.Lifecare Institute of Medical Sciences and Research Ahmedabad Gujarat IndiaCompleted